Antidepressant fluoxetine and its potential against colon tumors

被引：18

作者：

Stopper, Helga ^{[1
]}

Garcia, Sergio Britto ^{[2
]}

Waaga-Gasser, Ana Maria ^{[3
]}

Kannen, Vinicius ^{[1
]}

机构：

[1] Univ Wurzburg, Dept Toxicol, Versbacher Str 9, D-97078 Wurzburg, Germany

[2] Univ Sao Paulo, Med Sch Ribeirao Preto, Dept Pathol, BR-14040902 Ribeirao Preto, SP, Brazil

[3] Univ Wurzburg, Dept Surg Mol Oncol & Immunol 1, D-97078 Wurzburg, Germany

来源：

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2014年 / 6卷 / 01期

基金：

巴西圣保罗研究基金会;

关键词：

Fluoxetine; Colon cancer; Cancer therapy; Tumor metabolism; SEROTONIN REUPTAKE INHIBITORS; SMOOTH-MUSCLE-CELLS; CANCER-ASSOCIATED FIBROBLASTS; ENDOTHELIAL PROGENITOR CELLS; OXIDATIVE STRESS; STEM-CELLS; SIGNALING PATHWAY; PERIPHERAL-BLOOD; DNA-SYNTHESIS; CARCINOMA;

D O I：

10.4251/wjgo.v6.i1.11

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colon cancer is one of the most common tumors worldwide, with increasing incidence in developing countries. Patients treated with fluoxetine (FLX) have a reduced incidence of colon cancer, although there still remains great controversy about the nature of its effects. Here we explore the latest achievements related to FLX treatment and colon cancer. Moreover, we discuss new ideas about the mechanisms of the effects of FLX treatment in colon cancer. This leads to the hypothesis of FLX arresting colon tumor cells at the at G(1) cell-cycle phase through a control of the tumor-related energy generation machinery. We believe that the potential of FLX to act against tumor metabolism warrants further investigation. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

引用

页码：11 / 21

页数：11

共 50 条

[21] A possible participation of transient receptor potential vanilloid type 1 channels in the antidepressant effect of fluoxetine
Manna, Shyamshree S. S.
Umathe, Sudhir N.
EUROPEAN JOURNAL OF PHARMACOLOGY, 2012, 685 (1-3) : 81 - 90
[22] Multispectral and Molecular Docking Studies Reveal Potential Effectiveness of Antidepressant Fluoxetine by Forming π-Acceptor Complexes
Gaber, Ahmed
Alsanie, Walaa F.
Alhomrani, Majid
Alamri, Abdulhakeem S.
Alyami, Hussain
Shakya, Sonam
Habeeballah, Hamza
Alkhatabi, Heba A.
Felimban, Raed, I
Alamri, Abdulwahab
Alhabeeb, Abdulhameed Abdullah
Raafat, Bassem M.
Refat, Moamen S.
MOLECULES, 2022, 27 (18):
[23] WHAT CONSTITUTES AN ADEQUATE ANTIDEPRESSANT TRIAL FOR FLUOXETINE
SCHWEIZER, E
RICKELS, K
AMSTERDAM, JD
FOX, I
PUZZUOLI, G
WEISE, C
JOURNAL OF CLINICAL PSYCHIATRY, 1990, 51 (01) : 8 - 11
[24] Timing of onset of antidepressant response with fluoxetine treatment
Nierenberg, AA
Farabaugh, AH
Alpert, JE
Gordon, J
Worthington, JJ
Rosenbaum, JF
Fava, M
AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (09): : 1423 - 1428
[25] ANTIDEPRESSANT FLUOXETINE AFFECTS THYROID HORMONE METABOLISM
Pavelka, Stanislav
JOURNAL OF PHYSIOLOGICAL SCIENCES, 2009, 59 : 272 - 272
[26] DNA-Binding Studies of Fluoxetine Antidepressant
Kashanian, Soheila
Javanmardi, Sanaz
Chitsazan, Arash
Omidfar, Kobra
Paknejad, Maliheh
DNA AND CELL BIOLOGY, 2012, 31 (07) : 1349 - 1355
[27] Contribution of the Opioid System to the Antidepressant Effects of Fluoxetine
Carazo-Arias, Elena
Nguyen, Phi T.
Kass, Marley
Jee, Hyun Jung
Nautiyal, Katherine M.
Magalong, Valerie
Coie, Lilian
Andreu, Valentine
Gergues, Mark M.
Khalil, Huzefa
Akil, Huda
Arcego, Danusa Mar
Meaney, Michael
Anacker, Christoph
Samuels, Benjamin A.
Pintar, John E.
Morozova, Irina
Kalachikov, Sergey
Hen, Rene
BIOLOGICAL PSYCHIATRY, 2022, 92 (12) : 952 - 963
[28] SERUM FLUOXETINE AND NORFLUOXETINE CONCENTRATIONS AND ANTIDEPRESSANT RESPONSE
KELLY, MW
PERRY, PJ
HOLSTAD, SG
GARVEY, MJ
THERAPEUTIC DRUG MONITORING, 1989, 11 (02) : 165 - 170
[29] Fluoxetine dose and outcome in antidepressant drug trials
Corrado Barbui
Matthew Hotopf
Silvio Garattini
European Journal of Clinical Pharmacology, 2002, 58 : 379 - 386
[30] Predictors of an acute antidepressant response to fluoxetine and sertraline
Flament, MF
Lane, RM
Zhu, R
Ying, Z
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1999, 14 (05) : 259 - 275

← 1 2 3 4 5 →